Ujin Pharma has filed draft papers for an IPO featuring a fresh issue of 1.18 crore shares. The company plans to use proceeds to repay debt and consolidate its associate firms. While FY25 revenue climbed 9.3% to Rs 1,628.8 crore, the 10.7% drop in profit highlights potential margin pressure, a key factor for potential investors to consider.
What Happened
Mumbai-based chemical supplier Ujin Pharma has officially submitted its Draft Red Herring Prospectus (DRHP) to the Securities and Exchange Board of India (SEBI) to launch an initial public offering (IPO). The company, which specializes in solvents and specialty chemicals, is looking to raise funds for debt repayment and to consolidate its business operations by investing in its associate companies.
The IPO Structure
The public offering consists of two main parts: a fresh issue of 1.18 crore equity shares and an offer-for-sale (OFS) of 72.82 lakh shares by existing shareholders. In an offer-for-sale, the money from the shares sold by existing shareholders goes directly to them, not to the company's business account. The fresh issue, however, will bring new capital into the company to support its growth plans.
Financials: Growth Versus Profitability
For the fiscal year ending March 2025, Ujin Pharma reported revenues of Rs 1,628.8 crore, an increase of 9.3% from the previous year. However, the company's profit for the same period stood at Rs 14.3 crore, which is a 10.7% decline from the previous year's figure of Rs 16 crore.
This data reveals a thin net profit margin, as the company operates a high-volume distribution model. Investors often monitor such figures closely, as a scenario where revenue increases but profit declines suggests that expenses—such as logistics, raw material costs, or operational overheads—are rising faster than the company can pass them on to customers.
Where The Money Will Go
Ujin Pharma intends to use Rs 61.7 crore of the IPO proceeds to invest in its associate firms, Altra Agro-Chem and Altra Pharma-Chem. The goal is to acquire additional equity stakes in these entities to make them subsidiaries of Ujin Pharma. This strategy suggests the company wants to bring these firms closer into its organizational structure. Additionally, the company has earmarked Rs 25 crore for the repayment of certain borrowings, which is aimed at lowering the company’s debt burden. The remaining funds are allocated for general corporate purposes.
Risks And Investor Monitorables
Investors may want to track how effectively the company manages its margins. The chemicals distribution sector, in which Ujin Pharma operates, is typically highly competitive with limited pricing power. Success depends heavily on efficient supply chain management, warehousing, and inventory turnover.
Key monitorables for investors include the company's ability to stabilize profit margins, the timeline for integrating the new subsidiaries, and the actual impact of the debt repayment on the company’s interest expenses. Prospective investors should also watch for any upcoming details regarding the pricing of the shares and the specific risk factors detailed in the final prospectus, as these will provide a clearer picture of the company's business stability.